Binds Expression Product Of Cancer-related Gene Or Fragment Thereof (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 530/387.7)
-
Patent number: 8350011Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: GrantFiled: August 2, 2007Date of Patent: January 8, 2013Assignee: MedImmune LimitedInventors: Susan Ann Cartlidge, Jianying Dong, Mark Hickinson, Ian Foltz, Jaspal Singh Kang
-
Patent number: 8338574Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.Type: GrantFiled: February 1, 2010Date of Patent: December 25, 2012Assignee: Xencor, Inc.Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
-
Patent number: 8338112Abstract: The invention relates to anti-hedgehog antibodies, their use in the detection of hedgehog expression in tissue, and to the use of such detection in the treatment of cancer.Type: GrantFiled: August 13, 2012Date of Patent: December 25, 2012Assignee: Genentech, Inc.Inventor: Suzanna J. Scales
-
Publication number: 20120321614Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies.Type: ApplicationFiled: April 24, 2012Publication date: December 20, 2012Applicants: Pfizer, Inc., Amgen Fremont Inc.Inventors: Neil R. Michaud, Shama Kajiji, Gary Borzillo, Vahe Bedian, Kevin Coleman, Larry L. Green, Xiao-Chi Jia
-
Publication number: 20120321628Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.Type: ApplicationFiled: June 8, 2012Publication date: December 20, 2012Applicant: Genentech, Inc.Inventors: Ralph H. Schwall, Kelly H. Tabor
-
Publication number: 20120321619Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 29 kDa C4.4a polypeptide, which is over expressed in several tumors, e.g. lung, colorectal, pancreas, prostate, renal and breast cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of C4.4a in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: December 8, 2010Publication date: December 20, 2012Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Lars Linden, Yong-Jiang Cao, Gabriele Leder, Beatrix Stelte-ludwig, Axel Harrenga, Ricarda Finnern, Frank Dittmer, Anke Mayer-Bartschmid, Juergen Franz, Simone Greven, Jörg Willuda, Jan Tebbe
-
Patent number: 8329421Abstract: Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and/or predict the aggressiveness of neoplasms.Type: GrantFiled: July 11, 2008Date of Patent: December 11, 2012Assignee: Ventana Medical Systems, Inc.Inventors: William C. Powell, Linda Willoughby Kivi, Patrick C. Roche, Gary Gooch, Fabien Gaire
-
Patent number: 8329875Abstract: Provided is a monoclonal antibody, or an antigen binding fragment thereof, which binds specifically to an epitope within the sequence KPGAKKDTKDSRPKL (Sequence ID No. 2) of AGR2. Such monoclonal antibodies are of prognostic and diagnostic utility in the investigation of cancer, particularly metastatic cancer. The antibodies described may also be used in prognosis or diagnosis of inflammatory diseases. Also provided are kits and solid supports comprising such antibodies, as well as the therapeutic use of antibodies of the invention.Type: GrantFiled: August 28, 2007Date of Patent: December 11, 2012Assignee: The University Of LiverpoolInventors: Roger Barraclough, Dong Liu Barraclough, Philip Rudland
-
Patent number: 8329873Abstract: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.Type: GrantFiled: November 20, 2007Date of Patent: December 11, 2012Assignees: The Regents of the University of California, Fox Chase Cancer CenterInventors: Gregory P. Adams, Eva M. Horak, Louis M. Weiner, James D. Marks
-
Publication number: 20120309942Abstract: The invention provides a fully human anti-HER2 monoclonal antibody, which has an amino acid sequence of heavy chain variable region as shown in SEQ ID NO: 6 and an amino acid sequence of light chain variable region as shown in SEQ ID NO: 8. The invention also discloses the nucleotide sequence encoding the antibody, the expression vector and the host cell comprising the nucleotide sequence, and the use of the antibody for manufacturing the medicament for the treatment of tumor.Type: ApplicationFiled: April 16, 2010Publication date: December 6, 2012Applicant: Shanghai Biomabs Pharmaceuticals Co., LTD.Inventors: Chuan Li, Xin Tong, Ying Kan
-
Patent number: 8323644Abstract: A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a yeast beta-glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal. The above therapeutic composition may further comprise antitumor antibodies or cancer vaccine composition, wherein the antitumor activities of the antitumor antibodies or the cancer vaccine composition are enhanced by the yeast glucan.Type: GrantFiled: January 17, 2007Date of Patent: December 4, 2012Assignees: Sloan-Kettering Institute for Cancer Research, Biotec Pharmacon ASAInventors: Nai-Kong V. Cheung, Rolf Einar Engstad
-
Patent number: 8323916Abstract: Nucleic acids encoding fibrocystin-L polypeptides and fibrocystin-L polypeptides are provided. Antibodies against the polypeptides, vectors and host cells containing the nucleic acids, methods for using the nucleic acids and polypeptides, and compositions and articles of manufacture also are provided.Type: GrantFiled: June 28, 2011Date of Patent: December 4, 2012Assignee: Mayo Foundation for Medical Education and ResearchInventors: Peter C. Harris, Marie C. Hogan, Christopher J. Ward, Matthew D. Griffin
-
Patent number: 8324351Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.Type: GrantFiled: February 1, 2010Date of Patent: December 4, 2012Assignee: Xencor, Inc.Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
-
Patent number: 8318907Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.Type: GrantFiled: February 1, 2010Date of Patent: November 27, 2012Assignee: Xencor, Inc.Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
-
Patent number: 8318165Abstract: The present invention provides isolated antibodies (e.g., humanized or human antibodies) that bind to the membrane-proximal domain (MP) of human Melanoma-Associated Chondroitin Sulphate Proteoglycan (MCSP), and are capable of mediating cytolysis of a cell expressing MCSP in the presence of human effector cells or complement. Methods of using such antibodies to induce cytolysis (e.g., ADCC or CDCC) of cells expressing MP-MCSP are also provided.Type: GrantFiled: September 10, 2007Date of Patent: November 27, 2012Assignee: Celldex Therapeutics Inc.Inventors: Tibor Keler, Laura A. Vitale, Lizhen He
-
Patent number: 8309315Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.Type: GrantFiled: August 25, 2008Date of Patent: November 13, 2012Assignees: Van Andel Research Institute, Fred Hutchinson Cancer Research CenterInventors: Boliang Cao, George F. Vande Woude, Beatrice S. Knudsen, Ping Xu Zhao
-
Publication number: 20120282633Abstract: Disclosed is a means for accurately measuring activated EGFR regardless of whether phosphorylation has occurred or not. The antibody or antigen-binding fragment thereof according to the present invention can bind to activated EGFR regardless of whether the activated EGFR is in a phosphorylated form or in a nonphosphorylated form. By carrying out an immunoassay using the antibody or antigen-binding fragment thereof, activated EGFR in a sample can be measured more accurately than by conventional methods. Abnormal activation of EGFR is responsible for the onset of cancer, and is regarded as a therapeutic target. Therefore, the antibody or antigen-binding fragment thereof according to the present invention is also useful for detection of cancers, in particular, cancers to which a molecular target drug(s) whose target is EGFR is(are) to be administered.Type: ApplicationFiled: January 7, 2011Publication date: November 8, 2012Inventors: Nobuyuki Ise, Kazuya Omi
-
Publication number: 20120282258Abstract: The invention relates to cytokine receptor-like factor 2 (CRLF2), and particularly certain mutant forms of CRLF2, as prognostic and therapeutic targets in precursor B-cell acute lymphoblastic leukemia (B-ALL). Mutant CRLF2 with a Phe232-Cys (F232C) mutation is overexpressed and constitutively activates STAT5 in a subset of B-ALL patients with particularly poor prognosis. Methods and compositions useful for identifying, inhibiting expression, and inhibiting activity of the mutant CRLF2 are provided. Also provided are methods and compositions useful for treating B-ALL.Type: ApplicationFiled: November 24, 2010Publication date: November 8, 2012Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: David Weinstock, Akinori Yoda
-
Publication number: 20120269814Abstract: The present invention provides compositions and methods utilizing antagonistic antibodies which specifically bind to human c-MPL (e.g., TPO-R).Type: ApplicationFiled: November 10, 2010Publication date: October 25, 2012Applicant: AMGEN INC.Inventors: Ping Wei, Aaron George Winters, Christina Abbott
-
Patent number: 8287865Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.Type: GrantFiled: July 29, 2010Date of Patent: October 16, 2012Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20120258998Abstract: A method of treating or preventing a gastrointestinal cancer by inhibiting expression of a CD44-SLC1A2 fusion gene or a functional variant thereof, or by inhibiting the activity of a fusion protein expressed by the CD44-SLC1A2 fusion gene or the functional variant thereof.Type: ApplicationFiled: April 5, 2011Publication date: October 11, 2012Inventors: Patrick Tan, Jiong Tao
-
Patent number: 8277803Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: GrantFiled: August 16, 2011Date of Patent: October 2, 2012Assignee: Hoffman-La Roche Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa A. Popp
-
Publication number: 20120244076Abstract: Antibodies specifically bind only to a cancer specific proliferating cell nuclear antigen (csPCNA) isoform and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform. Methods and compositions to detect the presence of csPCNA isoform are disclosed.Type: ApplicationFiled: May 22, 2012Publication date: September 27, 2012Inventors: Robert J. HICKEY, Linda H. MALKAS, Lauren SCHNAPER
-
Publication number: 20120237518Abstract: The present invention relates to a monoclonal antibody or an antibody fragment thereof, which binds to the extracellular region of human Trop-2 with high affinity and exhibits high ADCC activity and high antitumor activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent or a diagnostic agent using the antibody fragment thereof.Type: ApplicationFiled: June 10, 2011Publication date: September 20, 2012Applicants: KYOWA HAKKO KIRIN CO., LTD, SAPPORO MEDICAL UNIVERSITYInventors: Miki YAMAGUCHI, Kazunori Kato, Hirofumi HAMADA, Kazuyasu NAKAMURA, Yoshiyuki SUGIMOTO, Tsuguo KUBOTA, Masahiro IKEDA
-
Publication number: 20120219501Abstract: Described are gynaecological cancer specific biomarkers comprising the nucleic acid sequence of the Engrailed-2 (EN2) gene or the amino acid sequence of the encoded EN2 protein. Also described are uses of the biomarkers in the treatment, diagnosis, monitoring and imaging of gynaecological cancer.Type: ApplicationFiled: July 13, 2010Publication date: August 30, 2012Inventors: Richard Morgan, Hardev S. Pandha
-
Publication number: 20120201824Abstract: The present invention includes compositions and methods for inhibiting an oncogenic protein or its down-stream effector protein to suppress expression of a cell-surface protein involved in inhibiting immune response against malignant cells thereby enhancing immunogenicity of a cell. The invention includes inhibitors of expression of CD274 and/or its functional cell-membrane bound immunosuppressive analog. The invention includes inhibitors of function or expression of oncogenic ALK tyrosine kinase and/or other oncogenic proteins responsible for induction of expression of CD274 or its functional immunosuppressive equivalent. The invention includes inhibitors of function or expression of STAT3 and/or other cell signal transmitters and/or transcription factors activated by ALK or its functional analog involved in induction of expression of CD274 or its functional analog.Type: ApplicationFiled: December 8, 2011Publication date: August 9, 2012Inventor: Mariusz Wasik
-
Patent number: 8236310Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.Type: GrantFiled: September 14, 2010Date of Patent: August 7, 2012Assignee: Agensys, Inc.Inventors: Aya Jakobovits, Steven B. Kanner, Pia M. Challita-Eid, Juan J. Perez-Villar, Daulet Satpaev, Arthur B. Raitano, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Xiao-chi Jia, Jean Gudas
-
Patent number: 8232069Abstract: The present invention aims at developing a gene delivery system which has a high selectivity to a target cell and can introduce and express a gene with high efficiency, particularly developing such a system for use in a gene delivery therapy using a viral vector. The present invention provides a method for targeting a drug, which comprises the step of delivering a drug containing a therapeutic gene to a target site using an anti-PAP2a antibody.Type: GrantFiled: May 17, 2006Date of Patent: July 31, 2012Assignee: Sapporo Medical UniversityInventors: Hirofumi Hamada, Kiminori Nakamura, Kazunori Kato
-
Publication number: 20120189633Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein.Type: ApplicationFiled: January 25, 2012Publication date: July 26, 2012Applicant: KOLLTAN PHARMACEUTICALS, INC.Inventors: Yaron Hadari, Elizabeth M. Mandel-Bausch, Susanne Radke, Joseph Schlessinger, Yoshihisa Suzuki
-
Patent number: 8221749Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: GrantFiled: July 29, 2011Date of Patent: July 17, 2012Assignee: Amgen Inc.Inventors: Thomas C. Boone, Jonathan D. Oliner
-
Patent number: 8216582Abstract: The present invention relates to polynucleotide and polypeptide sequences which are differentially expressed in cancer cells compared to normal cells. The present invention more particularly relates to the use of these sequences in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells.Type: GrantFiled: June 22, 2007Date of Patent: July 10, 2012Assignee: Alethia Biotherapeutics Inc.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Publication number: 20120171210Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating c-met dimerization and/or binding of ligand to c-met using a c-met antagonist that disrupts c-met multimerization.Type: ApplicationFiled: February 10, 2012Publication date: July 5, 2012Applicant: Genentech, Inc.Inventors: Monica Kong-Beltran, Dineli M. Wickramasinghe
-
Patent number: 8206711Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.Type: GrantFiled: December 2, 2009Date of Patent: June 26, 2012Assignees: Biogen Idec Inc., Genentech, Inc.Inventors: Christine A. White, Antonio J. Grillo-Lopez, John G. Curd, Susan Desmond-Hellmann
-
Patent number: 8207308Abstract: The present invention is related to complementarity determining region (cdr)-grafted humanized r24 antibodies that bind to the gd3 ganglioside antigen. The humanized antibodies disclosed herein have characteristics that are comparable or superior to the murine r24 antibody, and the humanized antibodies are useful in treating cancer (e.g. Melanoma).Type: GrantFiled: August 16, 2009Date of Patent: June 26, 2012Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Paul Chapman, Lisa Davidson, José W. Saldanha
-
Patent number: 8202969Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.Type: GrantFiled: December 3, 2010Date of Patent: June 19, 2012Assignees: Oregon Health & Science University, U.S. Department of Veteran Affairs, Dana-Farber Cancer Institute, Brigham and Women's HospitalInventors: Michael C. Heinrich, Christopher C. Corless, Jonathan A. Fletcher, George D. Demetri
-
Publication number: 20120149762Abstract: The present invention provides a novel human gene ZNFN3A1 whose expression is markedly elevated in a great majority of HCCs compared to corresponding non-cancerous liver tissues. The gene encodes a protein having a zinc finger domain as well as a SET domain and has been found to form a regulatory complex with RNA helicase and RNA polymerase.Type: ApplicationFiled: February 23, 2012Publication date: June 14, 2012Applicant: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Yoichi Furukawa
-
Patent number: 8198413Abstract: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.Type: GrantFiled: October 9, 2009Date of Patent: June 12, 2012Assignee: Pierre Fabre MedicamentInventor: Jean-François Haeuw
-
Publication number: 20120135018Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG anti-body. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting.Type: ApplicationFiled: April 28, 2010Publication date: May 31, 2012Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Shiv Srivastava, Shyh-Han Tan, Albert Dobi
-
Patent number: 8187889Abstract: Plasma samples of ovarian and breast cancer patients were used to search for markers of cancer, using two-dimensional gel electrophoresis and MALDI TOF mass spectrometry. Truncated forms of cytosolic serine hydroxymethyl transferase (cSHMT), T-box transcription factor 3 (Tbx3) and utrophin were aberrantly expressed in samples from cancer patients, as compared to samples from noncancer cases. Aberrant expression of proteins was validated by immunoblotting of plasma samples with specific antibodies to cSHMT, Tbx3 and utrophin. A cohort of 79 breast and 39 ovarian cancer patients, and 31 individuals who were either healthy or had noncancerous conditions was studied. We observed increased expression of truncated cSHMT, Tbx3 and utrophin in plasma samples obtained from patients at early stages of disease. The results indicate that cSHMT, Tbx3, utrophin and truncated forms thereof can be used as components of multiparameter monitoring of ovarian and breast cancer.Type: GrantFiled: July 27, 2007Date of Patent: May 29, 2012Assignee: Ludwig Institute For Cancer Research Ltd.Inventors: Marta Lomnytska, Anna Dubrovska, Ulf Hellman, Nataliya Volodko, Serhiy Souchelnytskyi
-
Publication number: 20120121600Abstract: The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” or (ii) a CDR-H1 having the amino acid sequence “TYAMH” and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” and a CDR-H3 having the amino acid sequence “DRGLRFYFDY”. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.Type: ApplicationFiled: December 13, 2011Publication date: May 17, 2012Inventors: Doris RAU, Susanne Mangold, Peter Kufer, Tobias Raum
-
Patent number: 8173780Abstract: To provide a cancer diagnostic reagent for determining malignancy of a cancer patient or a cancer cell and a tendency of canceration of a healthy subject, the reagent including a peptide having an ability to activate a cancer-related gene and extracted from cell membrane surfaces of human squamous-cell carcinoma cells or including a synthetic polynucleotide encoding the peptide or a partial amino acid sequence of the peptide.Type: GrantFiled: July 16, 2009Date of Patent: May 8, 2012Inventor: Yasuiki Umezu
-
Publication number: 20120107306Abstract: The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.Type: ApplicationFiled: August 22, 2011Publication date: May 3, 2012Applicant: NOVARTIS AGInventors: Winfried ELIS, Seth ETTENGERG, Andrew Paul GARNER, Nicole HAUBST, Christian Carsten Silvester KUNZ, Elizabeth Anne Reisinger SPRAGUE
-
Patent number: 8168758Abstract: The invention provides antibodies having an antigenic binding site specifically directed against an MN protein, and methods for using such antibodies in treating and diagnosing an MN-related disorder.Type: GrantFiled: December 12, 2006Date of Patent: May 1, 2012Assignee: Bayer HealthCare LLCInventors: Paul Tamburini, Gerald Ranges, Lila Adnane, Timothy Mccabe, Pamela Trail, Sha Ha
-
Patent number: 8163552Abstract: A purified polypeptide that binds to neoplastic cells, which may be an antibody, is produced by the hybridoma SAM-6, a method for its production and use in the treatment and diagnosis of neoplasms.Type: GrantFiled: November 12, 2004Date of Patent: April 24, 2012Assignee: Patrys LimitedInventors: Heinz Vollmers, Hans-Konrad Müller-Hermelink
-
Patent number: 8158760Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: GrantFiled: January 9, 2009Date of Patent: April 17, 2012Assignee: Kyowa Hakko Kirin Co., LtdInventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
-
Publication number: 20120089541Abstract: The present invention concerns cancer biomarkers. In particular, the invention concerns c-met as biomarkers for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.Type: ApplicationFiled: August 31, 2011Publication date: April 12, 2012Applicant: Genentech, Inc.Inventors: Premal H. Patel, Amy C. Peterson, Robert L. Yauch, Jiping Zha
-
Publication number: 20120082663Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.Type: ApplicationFiled: July 28, 2011Publication date: April 5, 2012Applicant: Genentech, Inc.Inventors: Mark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
-
Publication number: 20120082662Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.Type: ApplicationFiled: July 28, 2011Publication date: April 5, 2012Applicant: Genentech, Inc.Inventors: Mark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
-
Patent number: 8147836Abstract: Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis.Type: GrantFiled: December 17, 2008Date of Patent: April 3, 2012Assignee: Dyax Corp.Inventors: Clive R. Wood, Daniel T. Dransfield, Laetitia Devy
-
Patent number: 8129506Abstract: The present invention provides for chimeric proteins comprising a MUC1 extracellular (MUC1-EC) polypeptide and a carrier polypeptide that function as traps for MUC1 ligands.Type: GrantFiled: October 21, 2004Date of Patent: March 6, 2012Assignees: Genzyme Corporation, Dana-Farber Cancer Institute, Inc.Inventors: Surender Kharbanda, Donald W. Kufe